+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A



Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A



Blood 124(15): 2333-2336



The risk for inhibitor development in mild hemophilia A (factor VIII levels between 5 and 40 U/dL) is larger than previously anticipated, continues throughout life, and is particularly associated with certain mutations in F8. Desmopressin may reduce inhibitor risk by avoiding exposure to FVIII concentrates, but the heterogenous biological response to desmopressin, showing large interindividual variation, may limit its clinical use. However, predictors of desmopressin response have been recently identified, allowing the selection of the best candidates to this treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054432329

Download citation: RISBibTeXText

PMID: 25139352

DOI: 10.1182/blood-2014-02-546127


Related references

Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A. Seminars in Thrombosis and Hemostasis 42(5): 507-512, 2017

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. Journal of Thrombosis and Haemostasis 9(3): 423-427, 2011

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. Journal of Thrombosis and Haemostasis 6(12): 2048-2054, 2008

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. Journal of Thrombosis and Haemostasis 7(6): 930-937, 2009

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. Seminars in Hematology 43(1 Suppl 1): S3-S9, 2006

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 101(4): 1351-1358, 2003

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of Thrombosis and Haemostasis 1(6): 1228-1236, 2003

Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia. Zhonghua Er Ke Za Zhi 51(8): 631-634, 2013

Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children. Zhongguo Dang Dai Er Ke Za Zhi 13(9): 715-717, 2011

Hemophilia in the female; example of a clinical case of mild hemohemophilia in the mother of a patient with classic hemophilia. Haematologica 43(10): 993, 1958

Clinical efficacy and determinants of response to treatment with desmopressin in mild hemophilia a. Seminars in Thrombosis and Hemostasis 39(7): 732-739, 2013

The pattern of germline mutations in Mexicans with hemophilia B Evidence for a small mutational target size in mild or borderline mild-moderate hemophilia B. American Journal of Human Genetics 55(3 Suppl. ): A246, 1994

More on: mild hemophilia A and inhibitor development. Journal of Thrombosis and Haemostasis 2(4): 676; Author Reply 677, 2004

A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only Clinical features, surgical management and partial characterization of the inhibitor. Blood 90(10 Suppl. 1 Part 1): 36A, 1997

Factor viii inhibitor in mild hemophilia. Thrombosis Research (Suppl. 6): 43, 1986